Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Administratiekantoor eTheRNA Immunotherapies from Niel, company number BE0741658931, closed financial year 2025 with a result of € -66 after tax. For that financial year Administratiekantoor eTheRNA Immunotherapies recorded a gross margin of € -66 and equity of € -2,535. Compared with financial year 2024, the result moved from € -139 to € -66. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ -2,535
▼ € 66 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -66
▲ 53 % less loss than in 2024
Profit after tax over the fiscal year.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -264 | € -14 | € -85 | € -66 | ▲ € 19 |
| Profit after taxes | € -365 | € -119 | € -139 | € -66 | ▲ € 73 |
| Equity | € -2,211 | € -2,330 | € -2,469 | € -2,535 | ▼ € 66 |
| Total debts | € 2,211 | € 2,330 | € 2,469 | € 2,535 | ▲ 3% |
| Retained profit | € -2,211 | € -2,330 | € -2,469 | € -2,535 | ▼ € 66 |
Key figures of Administratiekantoor eTheRNA Immunotherapies, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Administratiekantoor eTheRNA Immunotherapies?
What happened at Administratiekantoor eTheRNA Immunotherapies in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 66. Source: NBB ↗
- etherna immunotherapies NV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 365 loss in 2022 to € 66 loss in 2025.
Management
The stake of ETHERNA IMMUNOTHERAPIES comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Administratiekantoor eTheRNA ImmunotherapiesBehind Administratiekantoor eTheRNA Immunotherapies is etherna immunotherapies NV. The shares are held by ETHERNA IMMUNOTHERAPIES (100%).
Directors
According to the 2025 annual accounts
since 2022
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Galileilaan 19
2845 Niel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0741.658.931
- VAT number
- BE 0741.658.931
- Registered office
- Galileilaan 19, 2845 Niel
- Names & denominations
- Administratiekantoor eTheRNA Immunotherapies
- Enterprise type
- Rechtspersoon
- Legal form
- Private foundation
- Legal situation
- Normale toestand
- Start date
- 16 January 2020
- Peppol
- Not registered